On May 17, 2023 Clinical stage oncology company Prescient Therapeutics (ASX: PTX) reported that it will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy (ISCT) in France later this month (Press release, Prescient Therapeutics, MAY 16, 2023, View Source [SID1234631811]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prescient researchers will showcase new preclinical data on the company’s next-generation immune receptor platform OmniCAR and its cell therapy enhancement platform CellPryme.

Both abstracts will also be published in the next issue of the ISCT’s official journal Cytotherapy.

The ISCT is focused on pre-clinical and translational aspects of cell and gene-based therapeutic developments and aims to advance scientific research into innovative treatments for patients.

The annual conference brings together clinicians, regulators, researchers and industry partners with a shared vision to translate cell and gene technologies into safe and effective therapies.

It attracts more than 2700 experts from 60 countries each year.